- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03943004
Trial of DFP-14927 in Advanced Solid Tumors
A Phase I Study of DFP-14927 in Patients With Advanced Solid Tumors
Study Overview
Detailed Description
This study will determine the safety and efficacy of DFP-14927 in patients with refractory or relapsed advanced solid tumors. The study will be guided by a standard "3+3"dose escalation by observing the drug-related toxicities and dose-limiting toxicities following weekly IV infusion of DFP-14927 for each 28-day cycle (4 doses per cycle). In addition, the maximum-tolerated dose and recommended Phase II dose for DFP-14927 will be determined.
Furthermore, the study will determine the pharmacokinetics and bioavailability of DFP-14927 during the first cycle of treatment using the weekly dosing schedule.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA Department of Medicine- Hematology/Oncology
-
Contact:
- Lisa Yonemoto
- Phone Number: 310-582-4069
- Email: lyonemoto@mednet.ucla.edu
-
Principal Investigator:
- Zev Wainberg, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Jackie Smith, R.N.
- Phone Number: 713-745-3917
- Email: JSmith19@mdanderson.org
-
Principal Investigator:
- Jaffer Ajani, M.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically (or cytologically) confirmed diagnosis of solid tumor, refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available. Note: For expansion cohorts patients must have histologically (or cytologically) confirmed diagnosis of gastroesophageal cancer, pancreatic cancer, or cholangiocarcinoma that has relapsed or is refractory to standard therapy.
- Aged ≥ 18 years.
- ECOG Performance Status of 0 or 1.
Adequate clinical laboratory values defined as:
- absolute neutrophil count ≥ 1.5 x 10⁹/L
- platelets ≥ 100 x 10⁹/L
- hemoglobin ≥ 9.0 g/dL (transfusions permissible)
- plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)
- total bilirubin ≤ 1.5 x ULN
- alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (<5 x ULN if documented hepatic metastases)
- prothrombin time (PT) ≤1.2 x ULN, partial thromboplastin time (PTT) ≤ 1.2 ULN, and international normalized ratio (INR) ≤ 1.5
- Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, uncontrolled diabetes mellitus, or other organ dysfunctions.
- Patients may have measurable or non-measurable disease as defined by RECIST 1.1.
- Signed Informed-consent prior to the start of any study specific procedures.
- Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.
Exclusion Criteria:
- Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 half-lives for targeted therapies prior to this study entry.
- Have not recovered from adverse events (must be Grade ≤1) due to agents administered more than 4 weeks earlier.
- Have had any major bleeding episodes (variceal bleeds, hemorrhagic strokes, internal abdominal bleeds, etc.) within 6 months prior to starting study drug.
- Known hypersensitivity to any study drug component (such as pegylated medications).
- Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.
- Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance.
- Pregnant or lactating individuals.
- Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.
- Known history of HIV, HBV or HCV infection.
- Documented or known bleeding disorder.
- Requirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).
- Clinically evident CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy; history of seizure disorder not controlled by anti-seizure medication at the time of enrollment. Patients with primary CNS malignancies are excluded.
Patients with a significant cardiovascular disease or condition, including:
- Myocardial infarction within 6 months of study entry
- NYHA Class III or IV heart failure
- Uncontrolled dysrhythmias or poorly controlled angina.
- History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row) and/or risk factors (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
- Baseline prolongation of QT/QTc interval (repeated demonstration of QTc ≥ 450 msec for men and 470 msec for women). QTc values up to 500 msec will be acceptable where patient's medical history, e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DFP-14927
DFP-14927: weekly IV infusion, 28 day treatment cycle
|
DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule.
DFP-10917 is a nucleoside analog similar to deoxycytidine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the maximum tolerated dose (MTD)
Time Frame: From first dose (Day 1) up to 30 days after last dose
|
The highest dose level at which less than one-third of at least 6 patients (i.e., 0 or 1 out of 6) experience a DLT
|
From first dose (Day 1) up to 30 days after last dose
|
Recommended Phase II Dose (RP2D)
Time Frame: From first dose (Day 1) up to 30 days after last dose
|
The maximum tolerated dose (MTD) of DFP-14927 at which the Phase II study will explore
|
From first dose (Day 1) up to 30 days after last dose
|
Dose-Limiting Toxicity (DLT)
Time Frame: From first dose (Day 1) up to 30 days after last dose
|
Determined through the frequency/severity of adverse events per CTCAE V5.0
|
From first dose (Day 1) up to 30 days after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine objective response rate (CR or PR) in response to DFP-14927 study treatment
Time Frame: At pre-study and every 8 weeks through study completion, an average of 6 months
|
Response to treatment will be assessed per RECIST 1.1
|
At pre-study and every 8 weeks through study completion, an average of 6 months
|
Duration of response
Time Frame: At pre-study and every 8 weeks through study completion, an average of 6 months
|
Number of days from the time of initial response (CR or PR) to disease progression or death
|
At pre-study and every 8 weeks through study completion, an average of 6 months
|
PK parameters to be determined using area under the concentration curve (AUC)
Time Frame: Cycle 1 (each cycle is 28 days), Day 1: 0, 1, 2, 4, 8, 24, 48, and 96 hours post-dose; Day 8: 0,1, 2, 4, 8, 24, 48, and 96 hours post-dose and predose on Days 15, 22, and 29 (same as Day 1 of next Cycle)
|
The concentration of DFP-14927 in blood plasma vs time
|
Cycle 1 (each cycle is 28 days), Day 1: 0, 1, 2, 4, 8, 24, 48, and 96 hours post-dose; Day 8: 0,1, 2, 4, 8, 24, 48, and 96 hours post-dose and predose on Days 15, 22, and 29 (same as Day 1 of next Cycle)
|
PK parameters to be determined using maximum drug concentration (Cmax)
Time Frame: Cycle 1 (each cycle is 28 days), Day 1: 0, 1, 2, 4, 8, 24, 48, and 96 hours post-dose; Day 8: 0,1, 2, 4, 8, 24, 48, and 96 hours post-dose and predose on Days 15, 22, and 29 (same as Day 1 of next Cycle)
|
The maximum concentration of DFP-14927 in blood plasma
|
Cycle 1 (each cycle is 28 days), Day 1: 0, 1, 2, 4, 8, 24, 48, and 96 hours post-dose; Day 8: 0,1, 2, 4, 8, 24, 48, and 96 hours post-dose and predose on Days 15, 22, and 29 (same as Day 1 of next Cycle)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaffer Ajani, MD, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D18-11161
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
University of Wisconsin, MadisonCompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Healthy Subject | Stage I Colorectal Cancer | Stage IIIA Colorectal Cancer | Stage IIIB Colorectal Cancer | Stage... and other conditionsUnited States
Clinical Trials on DFP-14927
-
Delta-Fly Pharma, Inc.CompletedAcute Myeloid Leukemia | Acute Lymphocytic LeukemiaUnited States
-
Delta-Fly Pharma, Inc.Completed
-
Azienda Ospedaliera V. CervelloCompletedBeta-Thalassemia | Thalassemia MajorItaly
-
Ain Shams UniversityUnknownSickle Cell Disease | Beta-thalassemia Major | Iron HemosiderosisEgypt
-
Delta-Fly Pharma, Inc.Not yet recruitingLeukemia, Myeloid, AcuteUnited States
-
ApoPharmaCompletedPantothenate Kinase-Associated NeurodegenerationUnited States, Germany, Italy, United Kingdom
-
ApoPharmaCompleted
-
ApoPharmaFood and Drug Administration (FDA)CompletedPantothenate Kinase-Associated NeurodegenerationUnited States, Germany, Italy, United Kingdom
-
ApoPharmaCompletedParkinson's DiseaseUnited Kingdom, France, Germany, Canada
-
University Hospital, LilleMinistry of Health, FranceActive, not recruitingAmyotrophic Lateral SclerosisFrance